Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan | Zendy

AI Assistant Blog Pricing

Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.